1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Hemangioma, Cavernous, Central Nervous System in 4 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Hemangioma, Cavernous, Central Nervous System: A vascular anomaly composed of a collection of large, thin walled tortuous VEINS that can occur in any part of the central nervous system but lack intervening nervous tissue. Familial occurrence is common and has been associated with a number of genes mapped to 7q, 7p and 3q. Clinical features include SEIZURES; HEADACHE; STROKE; and progressive neurological deficit.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The phenotypic manifestations of cerebral cavernous malformation disease caused by rare PDCD10 mutations have not been systematically examined, and a mechanistic link to Rho kinase-mediated hyperpermeability, a potential therapeutic target, has not been established." | 1.42 | Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. ( Akers, AL; Austin, C; Awad, IA; De Souza, JM; Gallione, CJ; Gunel, M; Lee, C; Marchuk, DA; McDonald, DA; Mikati, AG; Min, W; Rebeiz, T; Rorrer, A; Shenkar, R; Shi, C; Stockton, RA; Zhang, L, 2015) |
| "Familial cerebral cavernous malformations (CCMs) in humans result from mutations of CCM2 (malcavernin, OSM, MGC4607), PDCD10 (CCM3), or KRIT1 (CCM1), a Rap1 effector which stabilizes endothelial cell-cell junctions." | 1.36 | Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. ( Awad, IA; Ginsberg, MH; Shenkar, R; Stockton, RA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Detter, MR | 1 |
| Shenkar, R | 4 |
| Benavides, CR | 1 |
| Neilson, CA | 1 |
| Moore, T | 2 |
| Lightle, R | 2 |
| Hobson, N | 1 |
| Shen, L | 1 |
| Cao, Y | 2 |
| Girard, R | 2 |
| Zhang, D | 1 |
| Griffin, E | 1 |
| Gallione, CJ | 2 |
| Awad, IA | 4 |
| Marchuk, DA | 3 |
| Shi, C | 2 |
| Rebeiz, T | 1 |
| Stockton, RA | 2 |
| McDonald, DA | 2 |
| Mikati, AG | 1 |
| Zhang, L | 2 |
| Austin, C | 2 |
| Akers, AL | 1 |
| Rorrer, A | 2 |
| Gunel, M | 1 |
| Min, W | 1 |
| De Souza, JM | 1 |
| Lee, C | 1 |
| Wu, M | 1 |
| Zeineddine, HA | 1 |
| Gallione, C | 1 |
| Pytel, P | 1 |
| Liao, JK | 1 |
| Ginsberg, MH | 1 |
4 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Hemangioma, Cavernous, Central Nervous System
| Article | Year |
|---|---|
Novel Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Animals; Apoptosis Regulatory Proteins | 2020 |
Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Animals; Apoptosis Regulatory Prot | 2015 |
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Neoplasms; Disease Models, Animal; Fem | 2017 |
Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animal Structures; Animals; Brain Edema; Capillary Pe | 2010 |